Brawn Biotech

Which are the latest news on Brawn Biotech?

Why is Brawn Biotech Ltd falling/rising?

As of 19-Jun, Brawn Biotech Ltd's stock price is rising to 20.94, reflecting a 4.96% increase. This trend is supported by strong recent performance, outpacing the Sensex, and trading above key moving averages, despite a decline in investor participation.

As of 19-Jun, Brawn Biotech Ltd's stock price is rising, currently at 20.94, with a change of 0.99, reflecting an increase of 4.96%. This upward movement can be attributed to several factors. Over the past week, the stock has outperformed the Sensex, gaining 7.38% compared to the benchmark's 1.69%. Additionally, the stock has shown a strong performance in recent days, achieving a consecutive gain over the last three days with a total return of 13.01%.<BR><BR>Brawn Biotech is also trading above its moving averages across various time frames, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, indicating a positive trend in its price movement. However, it is worth noting that there has been a decline in investor participation, with delivery volume falling by 31.44% against the 5-day average as of June 17. Despite this decrease in participation, the stock remains liquid enough for trading, which may contribute to its current rise. Overall, the combination of recent gains, strong performance relative to the benchmark, and favorable moving averages supports the upward trend in Brawn Biotech Ltd's stock price.

Should I buy, sell or hold Brawn Biotech Ltd?

How big is Brawn Biotech?

As of 10th June, Brawn Biotech Ltd has a market capitalization of 6.00 Cr and reported net sales of 0.36 Cr and net profit of 0.21 Cr over the latest three quarters. Shareholder's funds are valued at 3.36 Cr, with total assets of 19.97 Cr.

As of 10th June, <BR><BR>Market Cap: Brawn Biotech Ltd has a market capitalization of 6.00 Cr, classified as a Micro Cap.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest three quarters is 0.36 Cr, while the sum of Net Profit for the same period is 0.21 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period for the latest annual data is March 2025. Shareholder's Funds are valued at 3.36 Cr, and Total Assets amount to 19.97 Cr.

Who are in the management team of Brawn Biotech?

The management team of Brawn Biotech consists of B R Gupta (Chairman & Managing Director), Brij Bala Gupta (Director), Subhash Chander (Independent Director), Kanta Takkar (Independent Director), and Priyanka Sharma (Company Secretary).

The management team of Brawn Biotech includes the following individuals:<BR><BR>1. B R Gupta - Chairman & Managing Director<BR>2. Brij Bala Gupta - Director<BR>3. Subhash Chander - Independent Director<BR>4. Kanta Takkar - Independent Director<BR>5. Priyanka Sharma - Company Secretary<BR><BR>If you need more information about their roles or the company, feel free to ask!

Who are the peers of the Brawn Biotech?

Brawn Biotech's peers include Beryl Drugs, Unjha Formulations, Decipher Labs, Vivanza Biosciences, Ganga Pharma, Shyama Computro, Fabino Enterprises, and Saroja Pharma. Brawn Biotech has below-average management and growth risks, with a 1-year return of 17.53%, while Beryl Drugs leads with 31.73% and Vivanza Biosciences lags at -29.75%.

Peers: The peers of Brawn Biotech are Beryl Drugs, Unjha Formul., Decipher Labs, Vivanza Biosci., Ganga Pharma., Shyama Computro., Fabino Enter, and Saroja Pharma In.<BR><BR>Quality Snapshot: Below Average management risk is observed at Beryl Drugs, Decipher Labs, Vivanza Biosci., Ganga Pharma., Brawn Biotech, and Fabino Enter, while Average management risk is found at Unjha Formul. and Saroja Pharma In. Below Average growth is noted for Beryl Drugs, Decipher Labs, Ganga Pharma., Brawn Biotech, Fabino Enter, and Vivanza Biosci., while Average growth is seen at Unjha Formul. and Saroja Pharma In. Capital Structure ratings show Good at Unjha Formul., Average at Ganga Pharma., and Below Average at Beryl Drugs, Decipher Labs, Vivanza Biosci., Brawn Biotech, Fabino Enter, and Shyama Computro.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Beryl Drugs at 31.73%, while the lowest is Vivanza Biosci. at -29.75%. Brawn Biotech's 1-year return of 17.53% is higher than that of Vivanza Biosci. Peers with a negative six-month return include Unjha Formul., Decipher Labs, Vivanza Biosci., Ganga Pharma., and Fabino Enter.

What does Brawn Biotech do?

Brawn Biotech Ltd is a healthcare group in the Pharmaceuticals & Biotechnology sector, reporting net sales of 2 Cr and a net profit of 1 Cr for the quarter ending March 2026, with a market cap of INR 6 Cr. The company has a P/E ratio of 6.00 and a return on equity of 25.41%.

Overview:<BR>Brawn Biotech Ltd is a fully integrated healthcare group operating in the Pharmaceuticals & Biotechnology industry within the Micro Cap market-cap bracket.<BR><BR>History:<BR>Brawn Biotech Ltd was originally incorporated as Brawn Pharmaceuticals Limited in November 1985. The company changed its name to Brawn Biotech Limited in November 2010. The most recent quarterly results reported net sales and net profit for the period ending March 2026.<BR><BR>Financial Snapshot:<BR>- Net Sales: 2 Cr (Quarterly Results - Mar 2026)<BR>- Net Profit: 1 Cr (Quarterly Results - Mar 2026)<BR>- Market-cap: INR 6 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>- P/E: 6.00<BR>- Industry P/E: 27<BR>- Dividend Yield: 0.00%<BR>- Debt Equity: -0.05<BR>- Return on Equity: 25.41%<BR>- Price to Book: 1.71<BR><BR>Contact Details:<BR>Address: C-64 Lajpat Nagar-1 1st Floor, New Delhi, New Delhi: 110024<BR>Email: solution@brawnpharma.com<BR>Website: http://www.brawnbiotech.com

Are Brawn Biotech Ltd latest results good or bad?

Brawn Biotech Ltd's latest results are concerning, showing a net loss of ₹0.04 crores in Q2 FY26, a 117.39% decline in profitability from the previous quarter, stagnant revenue, and deteriorating operating margins, indicating significant operational challenges and a troubling financial outlook.

Brawn Biotech Ltd's latest results indicate a troubling financial situation. In Q2 FY26, the company reported a net loss of ₹0.04 crores, a significant decline from a profit of ₹0.23 crores in the previous quarter, marking a dramatic 117.39% drop in profitability. Revenue remained stagnant at ₹0.12 crores, unchanged from the prior quarter, highlighting severe challenges in business momentum.<BR><BR>The operating margin has also deteriorated sharply, falling to -33.33% from a positive 25.0% in Q1 FY26. This indicates significant operational inefficiencies and cost pressures that the company has been unable to manage effectively. Additionally, the return on equity stands at a concerning -16.49%, reflecting the company's struggle to generate positive returns for shareholders.<BR><BR>Over the past five years, Brawn Biotech has seen its annual revenues plummet by 73.47%, raising fundamental concerns about the viability of its business model. The company's financial trajectory is characterized by persistent losses, minimal revenue growth, and a lack of institutional interest, which further complicates its outlook.<BR><BR>In summary, the latest results are indicative of a deteriorating financial condition, with multiple red flags suggesting that the company is facing significant operational and structural challenges.

When is the next results date for Brawn Biotech Ltd?

The next results date for Brawn Biotech Ltd is 29 May 2026.

The next results date for Brawn Biotech Ltd is scheduled for 29 May 2026.

How has been the historical performance of Brawn Biotech?

As of March 2023, Brawn Biotech reported net sales and total operating income of 0.48 crore, with a profit after tax of 0.19 crore and a PAT margin of 39.58%. The company has total assets and liabilities of 14.37 crore each, no debt, and stagnant cash flow, indicating limited operational activity and a need for revenue growth.

Answer:<BR>The historical performance of Brawn Biotech shows a modest financial position as of March 2023, with net sales reported at 0.48 crore and total operating income also at 0.48 crore. The company incurred total expenditure of 0.48 crore, resulting in an operating profit (PBDIT) of 0.24 crore after accounting for other income. The profit before tax stood at 0.22 crore, leading to a profit after tax of 0.19 crore, which translates to a PAT margin of 39.58%. The earnings per share (EPS) were recorded at 0.39, while the diluted EPS was slightly lower at 0.38. <BR><BR>In terms of assets and liabilities, Brawn Biotech's total assets as of March 2023 were 14.37 crore, with total liabilities at 14.37 crore, indicating a balanced sheet with no debt. The company's shareholder's funds were 6.31 crore, and the book value per share adjusted was 21.03. The cash flow results indicate that the company had no cash inflow or outflow from operating, investing, or financing activities, reflecting a stagnant cash position over the years. Overall, Brawn Biotech's financials suggest a company with limited operational activity and a need for growth in revenue generation. <BR><BR>Breakdown:<BR>Brawn Biotech's financial performance as of March 2023 reveals net sales of 0.48 crore, with total operating income matching this figure. The company faced total expenditures of 0.48 crore, leading to an operating profit of 0.24 crore, bolstered by other income. The profit before tax was 0.22 crore, resulting in a profit after tax of 0.19 crore, which corresponds to a PAT margin of 39.58%. The earnings per share were 0.39, while the diluted EPS was slightly lower at 0.38. On the balance sheet, total assets and liabilities were both at 14.37 crore, with shareholder's funds at 6.31 crore and a book value per share of 21.03. The cash flow statements indicate no activity in cash inflows or outflows, suggesting a lack of operational movement in the company's financial activities.

Is Brawn Biotech overvalued or undervalued?

As of June 11, 2024, Brawn Biotech is considered risky and overvalued due to its negative PE ratio of -2.75, poor financial metrics compared to peers, and a year-to-date stock performance decline of -23.04%.

As of 11 June 2024, Brawn Biotech's valuation grade has moved from does not qualify to risky, indicating a significant change in its perceived financial health. The company appears to be overvalued given its negative PE ratio of -2.75, an EV to EBIT of -2.48, and a ROCE of -47.62%. These ratios highlight the company's struggles in generating profits and returns on capital.<BR><BR>In comparison to its peers, Brawn Biotech's financial metrics stand out unfavorably. For instance, MMTC has a PE ratio of 119.39, while PTC India boasts a much more attractive PE of 9.02, showcasing the stark contrast in valuation within the industry. Additionally, Brawn Biotech's recent stock performance has been poor, with a year-to-date return of -23.04% compared to the Sensex's positive return of 5.58%, reinforcing the notion that the company is overvalued in its current state.

What is the technical trend for Brawn Biotech?

As of June 3, 2025, Brawn Biotech's trend has shifted to bearish with moderate strength, driven by daily moving averages and Bollinger Bands, despite mixed signals from the MACD and KST, and a year-to-date return of -19.29% compared to the Sensex's 5.51% gain.

As of 3 June 2025, the technical trend for Brawn Biotech has changed from mildly bearish to bearish. The current stance is bearish with moderate strength. Key indicators driving this include the daily moving averages indicating a bearish trend, and both the weekly and monthly Bollinger Bands confirming a bearish outlook. The MACD shows a mildly bullish signal on the weekly timeframe but is bearish on the monthly, indicating mixed signals. The KST is also mildly bullish weekly but bearish monthly, adding to the overall bearish sentiment. The stock's performance has been weak, with a year-to-date return of -19.29%, contrasting with the Sensex's positive return of 5.51%.

Who are the top shareholders of the Brawn Biotech?

The top shareholders of Brawn Biotech are primarily promoters, with Brij Raj Gupta holding the largest stake at 16.69%. Individual investors own 33.17% of the shares, while the highest public shareholder is Daksha Kotak at 1.24%.

The top shareholders of Brawn Biotech primarily include the promoters, with Brij Raj Gupta holding the largest individual stake at 16.69%. Additionally, individual investors collectively own 33.17% of the shares. The company has no pledged promoter holdings, and there are no foreign institutional investors (FIIs) involved. The highest public shareholder is Daksha Kotak, who holds 1.24%. Overall, the majority of the shares are held by the promoters.

Has Brawn Biotech declared dividend?

Brawn Biotech Ltd has declared a 10% dividend, amounting to 1 per share, with an ex-date of September 12, 2018. However, the company has shown significant losses over various periods, resulting in a consistent dividend yield of 0% in recent times.

Brawn Biotech Ltd has declared a 10% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 10%<BR>- Amount per share: 1<BR>- Ex-date: 12 Sep 18<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>In the 6 months period, the price return was -25.42%, the dividend return was 0%, resulting in a total return of -25.42%.<BR><BR>In the 1 year period, the price return was -37.33%, the dividend return was 0%, resulting in a total return of -37.33%.<BR><BR>In the 2 years period, the price return was 1.23%, the dividend return was 0%, resulting in a total return of 1.23%.<BR><BR>In the 3 years period, the price return was -13.68%, the dividend return was 0%, resulting in a total return of -13.68%.<BR><BR>In the 4 years period, the price return was -50.3%, the dividend return was 0%, resulting in a total return of -50.3%.<BR><BR>In the 5 years period, the price return was -40.15%, the dividend return was 0%, resulting in a total return of -40.15%.<BR><BR>Overall, while Brawn Biotech has declared a dividend, the total returns over various periods indicate significant losses, particularly in the longer term, suggesting challenges in the company's financial performance. The consistent dividend yield of 0% in recent periods further reflects a lack of ongoing dividend distributions.